Aspire Biopharma Holdings, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ASBP Nasdaq 2836 aspirebiolabs.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aspire Biopharma Holdings, Inc.

Aspire Biopharma Issues Shareholder Letter - May 28th, 2026 6:30 am
Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members - May 27th, 2026 6:30 am
Aspire Biopharma (ASBP) Authorizes $5M Share Repurchase Program - May 13th, 2026 11:46 am
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio - May 7th, 2026 9:00 am
ASBP: A Platform Approach to Drug Delivery with an Unconventional Path to Commercialization - Apr 30th, 2026 3:27 am
Aspire Biopharma Announces $5.0 Million Share Repurchase Program - Apr 27th, 2026 6:30 am
Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition - Apr 20th, 2026 6:30 am
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo - Apr 17th, 2026 6:00 am
Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue - Apr 16th, 2026 6:30 am
Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion - Apr 15th, 2026 6:00 am
Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion - Mar 19th, 2026 6:00 am
Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director - Mar 17th, 2026 6:30 am
Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026 - Mar 12th, 2026 6:00 am
Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack - Mar 10th, 2026 6:30 am
Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief - Mar 3rd, 2026 6:00 am
Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship - Feb 25th, 2026 6:30 am
Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements - Feb 20th, 2026 6:00 am
Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record - Feb 19th, 2026 6:00 am
Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R)) - Feb 17th, 2026 6:30 am
Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors - Feb 13th, 2026 6:00 am